FDA’s decision to end the erythropoiesis-stimulating agent (ESA) class REMS is yet another symbolic milestone for the agency in moving beyond the drug safety debates of the 2000s – and also a timely step to help advance the emerging era of biosimilars.
FDA announced April 13 that it is releasing Amgen from its formal Risk-Evaluation and Mitigation Strategy obligations for...



